These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35264224)

  • 1. Selective pressure of endocrine therapy activates the integrated stress response through NFκB signaling in a subpopulation of ER positive breast cancer cells.
    Semina SE; Pal P; Kansara NS; Huggins RJ; Alarid ET; Greene GL; Frasor J
    Breast Cancer Res; 2022 Mar; 24(1):19. PubMed ID: 35264224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor κB Pathways with Hybrid Drugs for Breast Cancer Therapy.
    Kastrati I; Siklos MI; Brovkovych SD; Thatcher GRJ; Frasor J
    Horm Cancer; 2017 Jun; 8(3):135-142. PubMed ID: 28396978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.
    Zhou Y; Yau C; Gray JW; Chew K; Dairkee SH; Moore DH; Eppenberger U; Eppenberger-Castori S; Benz CC
    BMC Cancer; 2007 Apr; 7():59. PubMed ID: 17407600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.
    Yde CW; Emdal KB; Guerra B; Lykkesfeldt AE
    Breast Cancer Res Treat; 2012 Aug; 135(1):67-78. PubMed ID: 22527100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.
    Kastrati I; Joosten SEP; Semina SE; Alejo LH; Brovkovych SD; Stender JD; Horlings HM; Kok M; Alarid ET; Greene GL; Linn SC; Zwart W; Frasor J
    Mol Cancer Res; 2020 Jul; 18(7):1018-1027. PubMed ID: 32245803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NFkappaB pathway and endocrine-resistant breast cancer.
    Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the Role of NFκB in Promoting Aggressive Phenotypes of Estrogen Receptor-Positive Breast Cancer.
    Smart E; Semina SE; Frasor J
    Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32887995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
    Miller TW; Balko JM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; González-Angulo AM; Mills GB; Miller WR; Wu H; Shyr Y; Arteaga CL
    Clin Cancer Res; 2011 Apr; 17(7):2024-34. PubMed ID: 21346144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms.
    Frasor J; El-Shennawy L; Stender JD; Kastrati I
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 3(0 3):235-9. PubMed ID: 25450861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
    Bergamaschi A; Christensen BL; Katzenellenbogen BS
    Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer.
    De Marchi T; Timmermans AM; Smid M; Look MP; Stingl C; Opdam M; Linn SC; Sweep FC; Span PN; Kliffen M; van Deurzen CH; Luider TM; Foekens JA; Martens JW; Umar A
    Oncotarget; 2016 Jan; 7(3):3098-110. PubMed ID: 26657294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.
    Notas G; Pelekanou V; Kampa M; Alexakis K; Sfakianakis S; Laliotis A; Askoxilakis J; Tsentelierou E; Tzardi M; Tsapis A; Castanas E
    Mol Oncol; 2015 Nov; 9(9):1744-59. PubMed ID: 26115764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interaction between ER and NFκB in resistance to endocrine therapy.
    Sas L; Lardon F; Vermeulen PB; Hauspy J; Van Dam P; Pauwels P; Dirix LY; Van Laere SJ
    Breast Cancer Res; 2012 Aug; 14(4):212. PubMed ID: 22963717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel ER-NFĸB-driven stem-like cell population associated with relapse of ER+ breast tumors.
    Semina SE; Alejo LH; Chopra S; Kansara NS; Kastrati I; Sartorius CA; Frasor J
    Breast Cancer Res; 2022 Dec; 24(1):88. PubMed ID: 36482488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer.
    Ojo D; Wu Y; Bane A; Tang D
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):735-745. PubMed ID: 29248549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoplasmic ERα and NFκB Promote Cell Survival in Mouse Mammary Cancer Cell Lines.
    Smart E; Alejo LH; Frasor J
    Horm Cancer; 2020 Apr; 11(2):76-86. PubMed ID: 32008217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.
    Bergamaschi A; Madak-Erdogan Z; Kim YJ; Choi YL; Lu H; Katzenellenbogen BS
    Breast Cancer Res; 2014 Sep; 16(5):436. PubMed ID: 25213081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.